Restless Legs Syndrome Therapeutics – Analysis, Clinical Trials and Developments

Press Release

Restless legs syndrome therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

According to the research, majority of pipeline drug candidates are being developed for oral administration. It has been observed that oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for RLS through the oral route has shown promising results in clinical studies.

Request for sample copy of this report at: https://www.pharmaproff.com/request-sample/1215

As of 2018, there are four marketed products available in the market. These drugs include Horizant, Requip, Neupro, and Mirapex. Therefore, with the emergence of late- and mid-stage pipeline products, the overall RLS therapeutics market is expected to grow significantly in the upcoming years.

Some of the key players involved in the development of RLS therapeutics in the late- and mid-stage include UCB Biopharma SPRL, GlaxoSmithKline plc, NLS-1 Pharma AG, Bioprojet SCR, and Boehringer Ingelheim International GmbH.

RLS Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Financial Sector

Comments are closed.